Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

NCT06234098 is registered in ClinicalTrials.gov with Alyssum Therapeutics as lead sponsor.

NCT NCT06234098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06234098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
Lead sponsor
Alyssum Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 13, 2024
Completion date
January 31, 2027
Enrollment
100 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor